Ye Zhang

Ms. Ye Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
YZYe Zhang
Ye Zhang
XTXiaoli Tan
Xiaoli Tan
SHShiyu Hu
Shiyu Hu
ZCZhifang Cui
Zhifang Cui
WCWenyu Chen
Wenyu Chen
Purpose: Chronic obstructive pulmonary disease (COPD) concurrent with respiratory failure (RF) is devastating, and may result in death and disability. Systemic immune-inflammation index (SII) is a new prognostic biomarker linked to unfavorable outcomes of acute coronary syndrome, ischemic stroke, and heart failure. Nonetheless, its role in COPD is rarely investigated. Consequently, this study intends to assess the accuracy of SII in predicting the prognosis of COPD. Patients and Methods: The clinical information was retrospectively acquired from the Medical Information Mart for Intensive Care-IV database. The outcomes encompassed the incidence of RF and mortality. The relationship between different SII and outcomes was examined utilizing the Cox proportional-hazards model and restricted cubic splines. Kaplan-Meier analysis was employed for all-cause mortality. Results: The present study incorporated 1653 patients. During hospitalization, 697 patients (42.2%) developed RF, and 169 patients (10.2%) died. And 637 patients (38.5%) died during long-term follow-up. Higher SII increased the risk of RF (RF: HR: 1.19, 95% CI 1.12– 1.28, P< 0.001), in-hospital mortality (HR: 1.22, 95% CI 1.07– 1.39, P=0.003), and long-term follow-up mortality (HR: 1.12, 95% CI 1.05– 1.19, P< 0.001). Kaplan-Meier analysis suggested a significantly elevated risk of all-cause death (log-rank P< 0.001) in patients with higher SII, especially during the short-term follow-up period of 21 days. Conclusion: SII is closely linked to an elevated risk of RF and death in COPD patients. It appears to be a potential predictor of the prognosis of COPD patients, which is helpful for the risk stratification of this population. However, more prospective studies are warranted to consolidate our conclusion.

1 January 2023 in Therapeutic Advances in Chronic Disease
Verified
Journal Article
Open access
WCWenyu Chen
Wenyu Chen
JHJie Huang
Jie Huang
ZCZhifang Cui
Zhifang Cui
LWLei Wang
Lei Wang
LDLiang Dong
Liang Dong
YZYe Zhang
Ye Zhang
Background: Pain is the most common cancer-related symptom, but it is often undertreated. Telemedicine is widely used in cancer treatment, but its effectiveness is uncertain. Objective: We aimed to evaluate the impact of telemedicine intervention on pain in patients with cancer. Design: Methodological quality and risk-of-bias evaluation were conducted, and the sources of heterogeneity were explored through subgroup analysis and sensitivity analysis. Data Sources and Methods: PubMed, Embase, Web of Science, Cochrane Library, and clinical trial databases were searched up to 16 August 2022. Randomized controlled trials of the impact of telemedicine intervention regarding pain in patients with cancer were included, and the results related to pain were extracted. Results: Twenty-one randomized controlled trials were selected from 1810 articles. A total of 1454 patients received telemedicine interventions, and 2213 received conventional medical services. Telemedical intervention had a positive effect on improving pain intensity [standard mean deviation (SMD) = −0.28, 95% confidence interval (CI): −0.49 to −0.06, p = 0.01] and pain interference (SMD = −0.41, 95% CI: −0.54 to −0.28, p < 0.00001), with statistical difference between the two groups. The subgroup analysis results showed that the telemedicine subgroup based on an application (SMD = −0.54, 95% CI: −0.91 to −0.18, p = 0.004) and the subgroup with intervention time ⩾ 6 months (SMD = −0.33, 95% CI: −0.52 to −0.13, p = 0.001), both demonstrated significant improvement regarding pain intensity, with significant statistical difference between the two groups. When the follow-up time was ⩾ 6 months, there was no significant difference (SMD = −0.24, 95% CI: −0.55 to 0.07, p = 0.13). Conclusion: Compared with conventional medical services, telemedicine intervention can improve the pain of patients with cancer and is effective and acceptable regarding symptom monitoring. Integrating telemedicine interventions into cancer pain management may be a feasible option. But its long-term effects still need to be confirmed with more high-quality randomized controlled trials in the future. Registration: https://www.crd.york.ac.uk/PROSPERO/ ; CRD42022361990

29 March 2022 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
WCWenyu Chen
Wenyu Chen
MYMing Yao
Ming Yao
LDLiang Dong
Liang Dong
PSPingyang Shao
Pingyang Shao
YZYe Zhang
Ye Zhang
BFBinjie Fu
Binjie Fu
Big data has been reported widely to facilitate epidemic prevention and control in health care during the coronavirus disease 2019 (COVID-19) pandemic. However, there is still a lack of practical experience in applying it to hospital prevention and control. This study is devoted to the practical experience of design and implementation as well as the preliminary results of an innovative big data-driven COVID-19 risk personnel screening management system in a hospital. Our screening system integrates data sources in four dimensions, which includes Health Quick Response (QR) code, abroad travelling history, transportation close contact personnel and key surveillance personnel. Its screening targets cover all patients, care partner and staff who come to the hospital. As of November 2021, nearly 690 000 people and 5.79 million person-time had used automated COVID-19 risk screening and monitoring. A total of 10 376 person-time (0.18%) with abnormal QR code were identified, 242 person-time with abroad travelling history were identified, 925 person-time were marked based on the data of key surveillance personnel, no transportation history personnel been reported and no COVID-19 nosocomial infection occurred in the hospital. Through the application of this system, the hospital's expenditure on manpower and material resources for epidemic prevention and control has also been significantly reduced. Collectively, this study has proved to be an effective and efficient model for the use of digital health technology in response to the COVID-19 pandemic. Based on the data from multiple sources, this system has an irreplaceable role in identifying close contacts or suspicious person, and can significantly reduce the social burden caused by COVID-19, especially the human resources and economic costs of hospital prevention and control. It may provide guidance for clinical epidemic prevention and control in hospitals, as well as for future public health emergencies.

7 May 2022 in Clinical Therapeutics
Verified
Journal Article
Closed access
LZLiansheng Zhang
Liansheng Zhang
XWXiaoqing Wang
Xiaoqing Wang
YZYe Zhang
Ye Zhang
WCWenyu Chen
Wenyu Chen

1 January 2023 in Therapeutic Advances in Chronic Disease
Verified
Journal Article
Open access
LWLin Wang
Lin Wang
WCWenyu Chen
Wenyu Chen
XXXiaofei Xu
Xiaofei Xu
WCWenbo Chen
Wenbo Chen
DBDerong Bao
Derong Bao
YXYufen Xu
Yufen Xu
Background: The role of postoperative radiotherapy (PORT) for patients with completely resected stage N2 non-small-cell lung cancer (NSCLC) has been controversial. This study aimed to investigate the efficacy of PORT and prognosis in these patients. Objectives: An updated meta-analysis was conducted in this study to investigate the efficacy of PORT and prognosis in patients with completely resected and pathologically confirmed stage N2 NSCLC. Design: This study is a systematic review and meta-analysis. Data source and methods: Databases were searched up to 2 March 2022. All trials on patients with completely resected and pathologically confirmed stage N2 NSCLC undergoing PORT were screened, and data indicators in the PORT and non-PORT groups were extracted, respectively. The effect of PORT on overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) was estimated. Subgroup and sensitivity analyses were performed. Results: In all, 20 studies involving 6340 patients were finally included. The PORT significantly increased OS [hazard ratio (HR) = 0.77, 95% CI: 0.71–0.84, p < 0.001), LRFS (HR = 0.63, 95% CI: 0.52–0.76, p < 0.001), and DFS (HR = 0.72, 95% CI: 0.63–0.82, p < 0.001) while it showed no significant difference in improving DMFS (HR = 0.86, 95% CI: 0.71–1.05, p = 0.14). Conclusion: Our results suggest that in the postoperative treatment of patients with completely resected and pathologically confirmed stage N2 NSCLC, the addition of PORT provides better local recurrence control and survival benefit, but no benefit for distant metastases. The PORT may be incorporated into the postoperative treatment options for some patients with high-risk factors. However, it needs to be validated by more prospective studies in the future. Trail registration: CRD42022314095.

2 April 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JWJunpei Wu
Junpei Wu
YZYe Zhang
Ye Zhang
JWJiaye Wang
Jiaye Wang
CCChengshui Chen
Chengshui Chen
SHShiyu Hu
Shiyu Hu
WCWenyu Chen
Wenyu Chen
Background: During the diagnosis and treatment of non–small cell lung cancer (NSCLC), detecting the risk of its recurrence in an early phase is still challenging. Recent studies have investigated the radiomics-based machine learning (ML) models for detecting the risk of recurrence in NSCLC. However, there is still insufficient systematic evidence to prove its efficiency. Objective: This study is designed to systematically evaluate the effectiveness of radiomics-based ML in predicting the risk of recurrence in NSCLC, aiming to provide evidence-based support for the subsequent development of scoring tools to forecast recurrence risk. Methods: For acquiring research on radiomics-based models for forecasting the risk of recurrence in NSCLC, Cochrane Library, Web of Science, PubMed, and Embase were systematically retrieved, up to October 24, 2025. Studies on analyzing the recurrence of NSCLC using radiomics-based ML were included, while those in which only texture analysis was conducted or radiomics-based ML was not constructed were excluded. The Radiomics Quality Score (RQS) was used to appraise the eligible studies. Subgroup analyses were conducted according to the variables of the model, the background of treatment, the stage of lung cancer, and the pathological type. Results: Ultimately, 30 eligible studies in total were included, covering 7964 patients with NSCLC. According to the meta-analysis, the c-index of radiomics-based ML models for forecasting the risk of recurrence in NSCLC was 0.850 (95% CI 0.834‐0.866, 95% prediction interval [PI] 0.623‐1.004) in the training set. Specifically, the pooled c-index was 0.876 (95% CI 0.853‐0.900) among the patients receiving the stereotactic body radiation therapy and 0.825 (95% CI 0.804‐0.848) among those who received surgeries combined with other adjuvant treatment regimens. The c-index of the radiomics-based ML models combined with clinical features for forecasting the risk of recurrence in NSCLC was 0.833 (95% CI 0.822‐0.854, 95% PI 0.717‐0.945) in the training set. In contrast, the c-index of radiomics-based ML models for forecasting the risk of recurrence in NSCLC was 0.878 (95% CI 0.854‐0.902, 95% PI 0.681‐1.000) in the validation set. The c-index of radiomics-based ML models combined with clinical features for forecasting the risk of recurrence in NSCLC was 0.854 (95% CI 0.830‐0.878, 95% PI 0.655‐0.992) in the validation set. The average RQS across the included studies was 27.4%, revealing methodological limitations and an absence of standardization. Conclusions: This study is the first to confirm that radiomics-based ML models effectively predict the risk of recurrence in NSCLC. This study provides evidence-based support for the subsequent development or updating of radiomics-based ML models. However, the current methodological application of radiomics remains concerning. Therefore, in the future, research should standardize the workflow for implementing radiomics-based ML and incorporate multicenter imaging data to enhance its generalizability.